Jardiance Drives Boehringer Ingelheim Through First Half, Market Volatility Expected To Continue
Total Pharma Sales Up By 4.4%
Boehringer Ingelheim’s sales were driven by Jardiance and Ofev in the first half of 2020, with contract manufacturing contributing with a 16% increase in sales; more details from the EMPEROR-Reduced Phase III study in heart failure are expected at this month’s European College of Cardiology meeting.
